In the Boardroom
Refine Search
Pharmaceutical
Privately-held Swiss drugmaker Helsinn Group has announced the appointment of Dr Melanie Rolli as group chief operating officer (COO), effective June 1, 2022. 19 May 2022
Pharmaceutical
German firm Fresenius Kabi, a specialist in medicines and technologies for infusion, transfusion and clinical nutrition, has recruited Brandee Pappalardo as senior vice president and chief medical officer for North America. 19 May 2022
Biotechnology
Gene therapy company Opus Genetics, which is developing treatments for inherited retinal diseases, today announced the appointment of Jennifer Hunt as chief development officer. 11 May 2022
Biotechnology
US start-up biotech MOMA Therapeutics, which is discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced the completion of a $150 million Series B financing. 10 May 2022
Biotechnology
Swiss antibody-drug conjugate specialist ADC Therapeutics today announced that Chris Martin has stepped down as chief executive of the company. 9 May 2022
Biotechnology
Enthera Pharmaceuticals, a privately-held Italian biotech developing biologics for selected autoimmune conditions based on the discovery of an apoptosis pathway, has named Aled Williams chief executive. 6 May 2022
Biotechnology
UK-based biotech Destiny Pharma today announced the appointment of Dr Yuri Martina as chief medical officer (CMO). 3 May 2022
Biotechnology
Coming out of stealth since its founding in 2019, US biotech Dianthus Therapeutics today announced the completion of its $100 million Series A financing led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company. 3 May 2022
Biotechnology
US messenger RNA (mRNA) therapeutics and vaccines specialist Moderna has announced that Arpa Garay will join the firm as chief commercial officer (CCO), effective Monday, May 31, 2022. She 28 April 2022
Biotechnology
Boston, USA-based biotech start-up Jnana Therapeutics today announced the appointment of Doug Pagán, as both chief financial and chief operating officer. 26 April 2022
Biotechnology
Privately-held French biotech focused on providing immuno-therapeutics Biomunex Pharmaceuticals today announces the appointment of Dr Simon Plyte as chief scientific officer (CSO) and as a member of its scientific advisory board. 25 April 2022
Biosimilars
German drugmaker STADA Arzneimittel will from June add to its team by welcoming Dr Christine Berndt as head of global development Specialties/Biosimilars. 22 April 2022
Biotechnology
Cancer-focused cell therapy company ImmPACT Bio USA today announced the appointment of Venkata Yepuri as chief operating officer. In this role, Mr Yepuri will oversee business operations across the company. 20 April 2022
Pharmaceutical
Cerevance, a private, UK headquartered clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the appointment of Craig Thompson as chief executive (CEO). 20 April 2022
Biotechnology
Biotech funder and incubator Flagship Pioneering today announced that Michael Severino is joining the company as chief executive (CEO)-partner. 13 April 2022
Biotechnology
Swiss rare diseases specialist Santhera Pharmaceuticals has appointed Shabir Hasham as chief medical officer (CMO) and a member of its executive management team, effective May 1. 13 April 2022
Biotechnology
Norwegian biopharma BerGenBio has appointed experienced oncologist Cristina Oliva as chief medical officer. 11 April 2022
Pharmaceutical
Danish CNS specialist Lundbeck said on Friday it has has appointed Joerg Hornstein as chief financial officer (CFO) and member of its executive management. He will assume the role no later than September 1, 2022, and he will be registered with the Danish Business Authority. 11 April 2022
Pharmaceutical
Swiss pharma giant Novartis has announced the introduction of a new, simpler organizational structure and operating model. 4 April 2022
Pharmaceutical
UK endocrine diseases specialist Diurnal Group today announced that, following 14 years with the company, Martin Whitaker has decided to step down as chief executive (CEO) and a member of the board of Diurnal, with immediate effect, to enable him to pursue other business opportunities. 4 April 2022
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze